doi: 10.1161/hc4301.098282
(Circulation. 2001;104:2194.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Nonselective Versus Selective ß-Adrenergic Receptor Blockade in Congestive Heart Failure
Differential Effects on Sympathetic Activity
From the Division of Cardiology, Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, and the Section of Cardiology, Department of Medicine, St Boniface Hospital, University of Manitoba (E.R.A.), Winnipeg, Canada.
Correspondence to John D. Parker, MD, Associate Professor of Medicine, Division of Cardiology, Mount Sinai Hospital, University of Toronto, 600 University Ave, Suite 1609, Toronto, Ontario, Canada M5G-1X5. E-mail jdp{at}inforamp.net
Background— Activation of the sympathetic nervous system has important prognostic implications in chronic heart failure. Nonselective versus selective ß-adrenergic receptor antagonists may have differential effects on norepinephrine release from nerve terminals mediated by prejunctional ß2-adrenergic receptors.
Methods and Results —— Thirty-six patients with chronic heart failure were randomized to the nonselective ß-blocker carvedilol or the selective ß-blocker metoprolol (double-blind). Measurements of hemodynamics and cardiac and systemic norepinephrine spillover as well as microneurographic recordings of muscle sympathetic nerve traffic were made before and after 4 months of therapy. In the carvedilol group (n=17), there were significant reductions in both total body (-1.7±0.5 nmol/min, P<0.01) and cardiac norepinephrine spillover (-87±29 pmol/min, P<0.01). By contrast, in the metoprolol group (n=14), there were no significant changes in total body or cardiac norepinephrine spillover. Responses in the carvedilol group were significantly different from those observed in the metoprolol group (P<0.05). Both agents caused a reduction in heart rate and increases in pulse pressure, although mean arterial pressure did not change. Importantly, microneurographic measures of sympathetic nerve traffic to skeletal muscle did not change in either group.
Conclusions— Therapy with carvedilol caused significant decreases in systemic and cardiac norepinephrine spillover, an indirect measure of norepinephrine release. Such changes were not observed in patients treated with metoprolol. There was no effect of either agent on sympathetic efferent neuronal discharge to skeletal muscle. These findings suggest that carvedilol, a nonselective ß-blocker, caused its sympathoinhibitory effect by blocking peripheral, prejunctional ß-adrenergic receptors.
Key Words: heart failure • receptors, adrenergic, beta • nervous system, autonomic • norepinephrine
This article has been cited by other articles:
 |
|
 |
|
  H. Murai, M. Takamura, M. Maruyama, M. Nakano, T. Ikeda, D. Kobayashi, K.-i. Otowa, H. Ootsuji, M. Okajima, H. Furusho, et al. Altered firing pattern of single-unit muscle sympathetic nerve activity during handgrip exercise in chronic heart failure J. Physiol., June 1, 2009; 587(11): 2613 - 2622. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. T. La Rovere, G. D. Pinna, R. Maestri, E. Robbi, A. Caporotondi, G. Guazzotti, P. Sleight, and O. Febo Prognostic implications of baroreflex sensitivity in heart failure patients in the beta-blocking era. J. Am. Coll. Cardiol., January 13, 2009; 53(2): 193 - 199. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. J. Vittorio, R. Zolty, M. E. Kasper, R. M. Khandwalla, D. S. Hirsh, C.-H. Tseng, U. P. Jorde, and K. Ahuja Differential Effects of Carvedilol and Metoprolol Succinate on Plasma Norepinephrine Release and Peak Exercise Heart Rate in Subjects With Chronic Heart Failure Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2008; 13(1): 51 - 57. [Abstract] [PDF]
|
|
|
|
 |
|
 W. J. Remme, J. G. Cleland, L. Erhardt, P. Spark, C. Torp-Pedersen, M. Metra, M. Komajda, C. Moullet, M. A. Lukas, P. Poole-Wilson, et al. Effect of carvedilol and metoprolol on the mode of death in patients with heart failure Eur J Heart Fail, November 1, 2007; 9(11): 1128 - 1135. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Fraga, F. G. Franco, F. Roveda, L. N.J. de Matos, A. M.F.W. Braga, M. U.P.B. Rondon, D. R. Rotta, P. C. Brum, A. C.P. Barretto, H. R. Middlekauff, et al. Exercise training reduces sympathetic nerve activity in heart failure patients treated with carvedilol Eur J Heart Fail, June 1, 2007; 9(6-7): 630 - 636. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Grassi, G. Seravalle, F. Quarti-Trevano, F. Scopelliti, R. Dell'Oro, G. Bolla, and G. Mancia Excessive Sympathetic Activation in Heart Failure With Obesity and Metabolic Syndrome: Characteristics and Mechanisms Hypertension, March 1, 2007; 49(3): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Al-Hesayen and J. D. Parker Adverse effects of atrioventricular synchronous right ventricular pacing on left ventricular sympathetic activity, efficiency, and hemodynamic status Am J Physiol Heart Circ Physiol, November 1, 2006; 291(5): H2377 - H2379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Nikolaidis, I. Poornima, P. Parikh, M. Magovern, Y.-T. Shen, and R. P. Shannon The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1871 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Spaak, Z. J. Egri, T. Kubo, E. Yu, S.-I. Ando, Y. Kaneko, K. Usui, T. D. Bradley, and J. S. Floras Muscle Sympathetic Nerve Activity During Wakefulness in Heart Failure Patients With and Without Sleep Apnea Hypertension, December 1, 2005; 46(6): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Petersson, P. Friberg, G. Lambert, and B. Rundqvist Decreased renal sympathetic activity in response to cardiac unloading with nitroglycerin in patients with heart failure Eur J Heart Fail, October 1, 2005; 7(6): 1003 - 1010. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kubo, J. D. Parker, E. R. Azevedo, D. J. Atchison, G. E. Newton, P. Picton, and J. S. Floras Vagal heart rate responses to chronic beta-blockade in human heart failure relate to cardiac norepinephrine spillover Eur J Heart Fail, August 1, 2005; 7(5): 878 - 881. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. K. Somers, A. S. Gami, and L. J. Olson Treating Sleep Apnea in Heart Failure Patients: Promises But Still No Prizes J. Am. Coll. Cardiol., June 21, 2005; 45(12): 2012 - 2014. [Full Text] [PDF]
|
|
|
|
|
|
A. Al-Hesayen, E. R. Azevedo, J. S. Floras, S. Hollingshead, G. D. Lopaschuk, and J. D. Parker Selective versus nonselective {beta}-adrenergic receptor blockade in chronic heart failure: differential effects on myocardial energy substrate utilization Eur J Heart Fail, June 1, 2005; 7(4): 618 - 623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. F. McBride and C. M. White Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET J. Clin. Pharmacol., January 1, 2005; 45(1): 6 - 24. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nemoto, P. Razeghi, M. Ishiyama, G. De Freitas, H. Taegtmeyer, and B. A. Carabello PPAR-{gamma} agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H77 - H82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cogliati, S. Colombo, T. G. Ruscone, D. Gruosso, A. Porta, N. Montano, A. Malliani, and R. Furlan Acute {beta}-Blockade Increases Muscle Sympathetic Activity and Modifies Its Frequency Distribution Circulation, November 2, 2004; 110(18): 2786 - 2791. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Neumann, G. Ligtenberg, L. Oey, H. A. Koomans, and P. J. Blankestijn Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal Failure J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2902 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Grassi, A. Vincenti, R. Brambilla, F. Q. Trevano, R. Dell'Oro, A. Ciro, G. Trocino, A. Vincenzi, and G. Mancia Sustained Sympathoinhibitory Effects of Cardiac Resynchronization Therapy in Severe Heart Failure Hypertension, November 1, 2004; 44(5): 727 - 731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Satwani, G. W. Dec, and J. Narula {beta}-Adrenergic Blockers in Heart Failure: Review of Mechanisms of Action and Clinical Outcomes Journal of Cardiovascular Pharmacology and Therapeutics, October 1, 2004; 9(4): 243 - 255. [Abstract] [PDF]
|
|
|
|
|
|
H. Rickli, S. Steiner, K. Muller, and O. M. Hess Betablockers in heart failure: Carvedilol Safety Assessment (CASA 2-trial) Eur J Heart Fail, October 1, 2004; 6(6): 761 - 768. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Blankestijn Sympathetic hyperactivity in chronic kidney disease Nephrol. Dial. Transplant., June 1, 2004; 19(6): 1354 - 1357. [Full Text] [PDF]
|
|
|
|
|
|
W. S. Akers and L. A. Cassis Presynaptic modulation of evoked NE release contributes to sympathetic activation after pressure overload Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2151 - H2158. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Graham, P. A. Smith, R. J. Huggett, J. B. Stoker, A. F. Mackintosh, and D. A.S.G. Mary Sympathetic Drive in Anterior and Inferior Uncomplicated Acute Myocardial Infarction Circulation, May 18, 2004; 109(19): 2285 - 2289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Bauman and R. L. Talbert Pharmacodynamics of{beta}-Blockers in Heart Failure: Lessons from the Carvedilol Or Metoprolol European Trial Journal of Cardiovascular Pharmacology and Therapeutics, April 1, 2004; 9(2): 117 - 128. [Abstract] [PDF]
|
|
|
|
|
|
H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Roveda, H. R. Middlekauff, M. U. P. B. Rondon, S. F. Reis, M. Souza, L. Nastari, A. C. P. Barretto, E. M. Krieger, and C. E. Negrao The effects of exercise training on sympathetic neural activation in advanced heart failure: A randomized controlled trial J. Am. Coll. Cardiol., September 3, 2003; 42(5): 854 - 860. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Bouzamondo, J.-S. Hulot, P. Sanchez, and P. Lechat Beta-blocker benefit according to severity of heart failure Eur J Heart Fail, June 1, 2003; 5(3): 281 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Aggarwal, M. D. Esler, M. J. Morris, G. Lambert, and D. M. Kaye Regional Sympathetic Effects of Low-Dose Clonidine in Heart Failure Hypertension, March 1, 2003; 41(3): 553 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. J. Vittorio, C. C. Lang, S. D. Katz, M. Packer, D. M. Mancini, and U. P. Jorde Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving {beta}-Blockers Circulation, January 21, 2003; 107(2): 290 - 293. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. N. Graham, P. A. Smith, J. B. Stoker, A. F. Mackintosh, and D. A.S.G. Mary Time Course of Sympathetic Neural Hyperactivity After Uncomplicated Acute Myocardial Infarction Circulation, August 13, 2002; 106(7): 793 - 797. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nemoto, M. Hamawaki, G. De Freitas, and B. A. Carabello differential effects of the angiotensin-converting enzyme inhibitor lisinopril versus the beta-adrenergic receptor blocker atenolol on hemodynamics and left ventricular contractile function in experimental mitral regurgitation J. Am. Coll. Cardiol., July 3, 2002; 40(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|